Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PC945 inhaled add-on therapy for treatment-refractory invasive pulmonary aspergillosis
MOH_2022-11-21_011957Phase 3Completed
- Sponsor
- Pulmocide
- Start
- Nov 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Acute Invasive Aspergillosis comparing Inhaled PC945 + standard antifungal therapy with Inhaled placebo + standard antifungal therapy (2 arms). Started Nov 2022; status: completed.
02
Drugs
opelconazole
03
Conditions
Acute Invasive Aspergillosis
Beyond the preview
Go deeper on MOH_2022-11-21_011957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-11-21_011957.